Unveiling the Impact of Transparency in Coverage Data on Healthcare Prices

By HEOR Staff Writer

October 30, 2023

The Role of Transparency in Coverage Data

In the realm of healthcare, the importance of transparency cannot be overstated. A recent study by Benjamin L. Chartock, PhD; Kosali Simon, PhD; Christopher M. Whaley, PhD, has shed light on how transparency in coverage (TiC) data can significantly influence prices for common healthcare services. The researchers examined TiC price data from Humana, a major national insurer in the USA, highlighting the potential uses of such data for future research.

Unravelling Price Variation

The study’s findings revealed substantial price variation for common healthcare services. The researchers focused on seven procedures, including both ‘shoppable’ and ‘non-shoppable’ services. Interestingly, the variation in prices for these services was similar, regardless of their ‘shoppability’. The study also noted that mean county-level prices were lowest in the central US and Florida, with higher prices observed in the upper-Midwest and Southeast.

The findings of the study make a compelling case for the necessity of further research into the factors that drive price variation in healthcare. The topic of whether or not these prices accurately reflect worth, or whether or not they are an indication of inequalities in market power and negotiation leverage, will need to be investigated more in the future. If the second possibility is correct, then there is an even greater requirement for regulations that guarantee competitive healthcare markets.

In conclusion, the study highlights the potential of informed healthcare consumerism as a lever for managing costs and enhancing patient happiness. It also opens up new possibilities for the use of TiC data in larger settings, which opens up new avenues for using TiC data.

Reference url

Recent Posts

Advancing Supply Chain Resilience in Europe’s Off-Patent Medicines Sector

By HEOR Staff Writer

April 28, 2026

In an interview with Adrian van den Hoven, Director General of Medicines for Europe, meaningful progress made in 2025 is highlighted, including the political agreement on the new EU ph...
Enhancing Breakthrough Medical Device Access: EMA’s New Pilot Program for Innovative Techno...
The European Medicines Agency (EMA) has launched a pilot programme to deliver breakthrough medical device access for high-risk technologies that address unmet medical needs. Starting 28 April 2026, the initiative offers enhanced scientific advice and priority access to expert panels for developer...
Medical Device Innovation South Africa: Breaking Down Systemic Barriers

By HEOR Staff Writer

April 27, 2026

Medical device innovation South Africa is hindered by deep structural obstacles that prevent locally developed technologies from reaching patients, despite the country’s considerable technical expertise. South Africa’s medical technology sector remains trapped in a cycle of heavy import dependenc...